| pubmed-article:20204367 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:20204367 | lifeskim:mentions | umls-concept:C1140680 | lld:lifeskim |
| pubmed-article:20204367 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:20204367 | lifeskim:mentions | umls-concept:C0013216 | lld:lifeskim |
| pubmed-article:20204367 | lifeskim:mentions | umls-concept:C0079083 | lld:lifeskim |
| pubmed-article:20204367 | lifeskim:mentions | umls-concept:C0144576 | lld:lifeskim |
| pubmed-article:20204367 | lifeskim:mentions | umls-concept:C1516119 | lld:lifeskim |
| pubmed-article:20204367 | lifeskim:mentions | umls-concept:C0600558 | lld:lifeskim |
| pubmed-article:20204367 | lifeskim:mentions | umls-concept:C0205195 | lld:lifeskim |
| pubmed-article:20204367 | lifeskim:mentions | umls-concept:C0205179 | lld:lifeskim |
| pubmed-article:20204367 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:20204367 | pubmed:dateCreated | 2010-4-14 | lld:pubmed |
| pubmed-article:20204367 | pubmed:abstractText | Sorafenib is a novel oral anticancer agent targeting signal transduction and angiogenic pathways through inhibitory effects against MAP kinases and vascular endothelial growth factor receptor-2. The objectives of this neoadjuvant phase II-trial in patients with advanced epithelial ovarian cancer were to assess the activity and tolerability of the combination therapy of carboplatin/paclitaxel with multi-target tyrosine kinase inhibitor sorafenib. | lld:pubmed |
| pubmed-article:20204367 | pubmed:language | eng | lld:pubmed |
| pubmed-article:20204367 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20204367 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:20204367 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20204367 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20204367 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20204367 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20204367 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20204367 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:20204367 | pubmed:month | May | lld:pubmed |
| pubmed-article:20204367 | pubmed:issn | 1432-0843 | lld:pubmed |
| pubmed-article:20204367 | pubmed:author | pubmed-author:KüblerKirsten... | lld:pubmed |
| pubmed-article:20204367 | pubmed:author | pubmed-author:RudlowskiChri... | lld:pubmed |
| pubmed-article:20204367 | pubmed:author | pubmed-author:HartmannGunth... | lld:pubmed |
| pubmed-article:20204367 | pubmed:author | pubmed-author:KuhnWaltherW | lld:pubmed |
| pubmed-article:20204367 | pubmed:author | pubmed-author:EckhardtMeike... | lld:pubmed |
| pubmed-article:20204367 | pubmed:author | pubmed-author:PölcherMartin... | lld:pubmed |
| pubmed-article:20204367 | pubmed:author | pubmed-author:CochChristoph... | lld:pubmed |
| pubmed-article:20204367 | pubmed:author | pubmed-author:WolfgartenMat... | lld:pubmed |
| pubmed-article:20204367 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:20204367 | pubmed:volume | 66 | lld:pubmed |
| pubmed-article:20204367 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:20204367 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:20204367 | pubmed:pagination | 203-7 | lld:pubmed |
| pubmed-article:20204367 | pubmed:meshHeading | pubmed-meshheading:20204367... | lld:pubmed |
| pubmed-article:20204367 | pubmed:meshHeading | pubmed-meshheading:20204367... | lld:pubmed |
| pubmed-article:20204367 | pubmed:meshHeading | pubmed-meshheading:20204367... | lld:pubmed |
| pubmed-article:20204367 | pubmed:meshHeading | pubmed-meshheading:20204367... | lld:pubmed |
| pubmed-article:20204367 | pubmed:meshHeading | pubmed-meshheading:20204367... | lld:pubmed |
| pubmed-article:20204367 | pubmed:meshHeading | pubmed-meshheading:20204367... | lld:pubmed |
| pubmed-article:20204367 | pubmed:meshHeading | pubmed-meshheading:20204367... | lld:pubmed |
| pubmed-article:20204367 | pubmed:meshHeading | pubmed-meshheading:20204367... | lld:pubmed |
| pubmed-article:20204367 | pubmed:meshHeading | pubmed-meshheading:20204367... | lld:pubmed |
| pubmed-article:20204367 | pubmed:meshHeading | pubmed-meshheading:20204367... | lld:pubmed |
| pubmed-article:20204367 | pubmed:meshHeading | pubmed-meshheading:20204367... | lld:pubmed |
| pubmed-article:20204367 | pubmed:meshHeading | pubmed-meshheading:20204367... | lld:pubmed |
| pubmed-article:20204367 | pubmed:meshHeading | pubmed-meshheading:20204367... | lld:pubmed |
| pubmed-article:20204367 | pubmed:meshHeading | pubmed-meshheading:20204367... | lld:pubmed |
| pubmed-article:20204367 | pubmed:year | 2010 | lld:pubmed |
| pubmed-article:20204367 | pubmed:articleTitle | Sorafenib in combination with carboplatin and paclitaxel as neoadjuvant chemotherapy in patients with advanced ovarian cancer. | lld:pubmed |
| pubmed-article:20204367 | pubmed:affiliation | Department of Gynecology and Obstetrics, Center for Integrated Oncology, Bonn University Medical Center, University Hospital of Bonn, Sigmund-Freud-Str 25, 53105 Bonn, Germany. | lld:pubmed |
| pubmed-article:20204367 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:20204367 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:20204367 | pubmed:publicationType | Clinical Trial, Phase II | lld:pubmed |
